Extracardiac Prothrombotic Effects of COVID-19

Kankaria, Rohan; Sanina, Cristina; Gabr, Mohamed; Wiley, Jose; Bortnick, Anna E.

doi:10.1016/j.ccl.2022.03.008

Cited by 2 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…150 This is in line with the robust body of literature now available investigating the magnitude of the prothrombotic effects of COVID-19, and potential utility of anticoagulant treatments, highlighting these phenomena as a primary pathophysiologic mechanism for many of the cardiovascular clinical presentations encountered. [151][152][153][154][155][156][157][158][159] Outside of ACS, life-prolonging and symptom-ameliorating procedures performed in the CCL, namely those performed for treatment of structural heart disease, required adaptation to the pandemic. 160 Again, professional society guidance on the triage of patients undergoing evaluation for or pending transcatheter valve therapies was put forth and of great utility to the interventional cardiology community.…”

Section: Acute Coronary Syndromes and Cardiac Catheterization Laborat...mentioning

confidence: 99%

Section: Acute Coronary Syndromes and Cardiac Catheterization Laborat...mentioning

confidence: 99%

See 1 more Smart Citation

Interaction of COVID-19 With Common Cardiovascular Disorders

Boulos

Freeman

Henry

et al. 2023

Circulation Research

View full text Add to dashboard Cite

The onset and widespread dissemination of the severe acute respiratory syndrome coronavirus-2 in late 2019 impacted the world in a way not seen since the 1918 H1N1 pandemic, colloquially known as the Spanish Flu. Much like the Spanish Flu, which was observed to disproportionately impact young adults, it became clear in the early days of the coronavirus disease 2019 (COVID-19) pandemic that certain groups appeared to be at higher risk for severe illness once infected. One such group that immediately came to the forefront and garnered international attention was patients with preexisting cardiovascular disease. Here, we examine the available literature describing the interaction of COVID-19 with a myriad of cardiovascular conditions and diseases, paying particular attention to patients diagnosed with arrythmias, heart failure, and coronary artery disease. We further discuss the association of acute COVID-19 with de novo cardiovascular disease, including myocardial infarction due to coronary thrombosis, myocarditis, and new onset arrhythmias. We will evaluate various biochemical theories to explain these findings, including possible mechanisms of direct myocardial injury caused by the severe acute respiratory syndrome coronavirus-2 virus at the cellular level. Finally, we will discuss the strategies employed by numerous groups and governing bodies within the cardiovascular disease community to address the unprecedented challenges posed to the care of our most vulnerable patients, including heart transplant recipients, end-stage heart failure patients, and patients suffering from acute coronary syndromes, during the early days and height of the COVID-19 pandemic.

show abstract

Section: Acute Coronary Syndromes and Cardiac Catheterization Laborat...mentioning

confidence: 99%

Section: Acute Coronary Syndromes and Cardiac Catheterization Laborat...mentioning

confidence: 99%

Interaction of COVID-19 With Common Cardiovascular Disorders

Boulos

Freeman

Henry

et al. 2023

Circulation Research

View full text Add to dashboard Cite

show abstract

“…The VTE frequency in COVID-19 initially reported was 20-43%, relative to various stages of the pandemic (on average 26%) . A meta-analysis of 48 studies (1) with 18094 patients showed an overall incidence of VTE of 17%, 12% for DVT (deep vein thrombosis) and 7% for pulmonary embolism (PE). The incidence of VTE was higher in ICU (45%), in severely ventilated, mechanically ventilated, hypoxaemic patients with numerous thrombogenic risk factors .…”

mentioning

confidence: 99%

Thromboprophylaxis in COVID-19

Vlădăreanu

Nistor

2022

Internal Medicine

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic and its specific respiratory pathology has generated extensive research that has highlighted the specific nature of the disease (COVID-19). Thrombotic processes in the macrocirculation and microcirculation were among the first reported, accompanying respiratory (pulmonary) manifestations. Of the COVID-19 complications, thrombosis in the venous system (venous thrombosis and pulmonary embolism) and the atrial system (stroke) are the most numerous and severe in terms of evolution and prognosis. The prophylaxis of thrombotic processes in COVID-19, initially empirical, has gained a scientific basis based on research and experience of clinicians. The current paper presents general data on macro- and microcirculatory thrombosis and the rationale for thromboprophylaxis. Thromboprophylaxis in non-hospitalized COVID-19 patients, “non-critical” and “critical” hospitalized patients and possible post-hospital thromboprophylaxis are presented. Heparins (HGMM and HNF) are the most commonly indicated and used antithrombotic agents. Other antithrombotic agents - antiplatelets and direct anticoagulants (oral - DOAC) have a very limited and possibly negative role in thromboprophylaxis in COVID-19.

show abstract

Extracardiac Prothrombotic Effects of COVID-19

Cited by 2 publications

References 55 publications

Interaction of COVID-19 With Common Cardiovascular Disorders

Interaction of COVID-19 With Common Cardiovascular Disorders

Thromboprophylaxis in COVID-19

Contact Info

Product

Resources

About